Are Incentives Out Of Balance With Patient Need?
Executive Summary
Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.
You may also be interested in...
Make It Better And Put More Money In – Industry On England’s New Innovative Medicines Fund
While they await further details on England’s new Innovative Medicines Fund, industry and other stakeholders are asking questions about how far the fund – due for launch later this year – will be adapted to fit non-cancer therapies.
UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date
Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.
Could Reformed HTA Be A Legacy Of COVID-19?
The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?